GH Research PLC
GH Research PLC (GHRS): 463 pipeline candidates · 139 upcoming catalysts · ~46 mo cash runway · 986 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
46.3 months
D/E 0.03 · 0% dilution
Lead: Phase 2
463 candidates
139 upcoming, next in ~6d
N/A
A transparent, data-derived signal for GH Research PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$246.3M
Quarterly Burn
$16.7M
Runway
46.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (463 candidates)
| Drug | Phase |
|---|---|
| ^1^1c-methionine | Phase 2 |
| ^1^8f-fluorodeoxyglucose | Phase 2 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
| 0.9 % | Phase 4 |
Showing 10 of 463 candidates. Sign up for full pipeline.
Upcoming Catalysts (139)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
52
Total value held
$619.4M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 10,763,288 | $151.3M |
| bvf inc/il | 8,650,158 | $121.6M |
| ra capital management, l.p. | 7,676,697 | $107.9M |
| rtw investments, lp | 5,933,815 | $83.4M |
| fmr llc | 5,136,045 | $72.2M |
| toronto dominion bank | 1,397,873 | $19.7M |
| millennium management llc | 937,898 | $13.2M |
| 5am venture management, llc | 572,665 | $8.1M |
| blackrock, inc. | 455,618 | $6.4M |
| ubs group ag | 412,416 | $5.8M |
Showing top 10 of 52 institutional holders of GH Research PLC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GH Research PLC's pipeline?
GH Research PLC (GHRS) has 463 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GH Research PLC's lead drug candidate?
GH Research PLC's most advanced tracked candidate is ^1^1c-methionine (Phase 2) for Ependymoma.
What is GH Research PLC's next catalyst?
GH Research PLC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immu" — expected June 24, 2026.
What is GH Research PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GH Research PLC has approximately 46.3 months of cash runway.
What is GH Research PLC's market capitalization?
GH Research PLC's market capitalization is approximately $1.6B.
Get the full picture on GH Research PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.